ArticleJournal of family medicine and primary care2026
Role of novel hematological biomarkers in assessing chronic obstructive pulmonary disease (COPD) patients and their public health implications.
Article in Journal of family medicine and primary care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Chronic obstructive pulmonary disease (COPD) is a progressive inflammatory lung disorder marked by airflow limitation, often exacerbated by systemic inflammation. Identifying reliable, cost-effective biomarkers to assess disease severity, and predict acute exacerbations remains a clinical priority. This study aimed to evaluates the utility of hematological biomarkers-Immature Platelet Fraction (IPF), Absolute Immature Platelet Count (AIPC), Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Systemic Immune Inflammation Index (SII) in assessing COPD severity and exacerbation risk. Methods: A retrospective cross-sectional study was conducted with 136 COPD patients at the All India Institute of Medical Sciences (AIIMS), Rajkot, India. Demographic, spirometric, and hematological data were analyzed using IBM SPSS v27. Statistical methods included Chi-square tests, independent sample t-tests, ANOVA with post-hoc Tukey analysis, and Pearson correlation. Results: Of the 136 patients (80% male, mean age 64 years), 37.5% experienced acute exacerbations. Significant associations were found between gender and exacerbation ( Conclusion: IPF, AIPC, NLR, PLR, and SII are elevated in severe COPD and during exacerbations, offering cost-effective tools for risk stratification and monitoring. These biomarkers can support public health initiatives by enabling early intervention, reducing healthcare costs, and improving outcomes in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.